Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sutro And Celgene Advance Drug Pact

by Rick Mullin
November 3, 2014 | A version of this story appeared in Volume 92, Issue 44

Sutro Biopharma and Celgene have embarked on a new collaboration around multispecific antibodies and antibody-drug conjugates (ADCs) in which Celgene will have exclusive rights to acquire Sutro. Under the agreement, Sutro will receive payments totaling $95 million, which includes an undisclosed equity investment. Sutro may also receive up to $90 million more during the initial term of the agreement. The new research engagement broadens a 2012 collaboration to develop ADCs and bispecific antibodies for two undisclosed targets.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.